mtm laboratories today announced that it has made two
new clinical research appointments to augment the team developing
screening and diagnostic assays based on mtm's proprietary p16INK4a
biomarker. Lisa Kaufman is heading Clinical Operations in the US while
Petra Klement is leading Clinical Operations in Europe.
Lisa Kaufman has a strong background and 15 years of experience in clinical research development and joins mtm from Wyeth where she has spent the last two years managing the application of biomarkers in clinical trials. Previous to that, Mrs. Kaufman was Director Clinical Affairs at Viacell and Associate Director of Clinical Operations at Shire Biologics. Mrs. Klement has spent 4 years in clinical research at Pfizer and 10 years working on the management of multi-national clinical trials in the leading European clinical research organisations AMS and Innovex.
"As mtm enters this crucial clinical phase in the development of our assays we are delighted to appoint two such experienced individuals," said Ruediger Ridder, Chief Scientific Officer of mtm laboratories. "We have now put in place the right team to coordinate pivotal trials demonstrating the clinical utility of our in vitro diagnostic products based on the p16INK4a technology for the use in cervical cancer screening and diagnosis."
mtm laboratories AG is a privately held company based in Heidelberg, Germany with a wholly owned subsidiary in Westborough (MA), USA. The ISO 9001 and ISO 13485 certified company develops In Vitro Diagnostic test systems for the early detection and diagnosis of cancer with a focus on cervical cancer screening, the largest screening market in oncology. Based on mtm's proprietary p16INK4a biomarker, the Company is in the process of developing and clinically validating cell-based CINtec(R) assays as well as non cell-based IVD products.
Lisa Kaufman has a strong background and 15 years of experience in clinical research development and joins mtm from Wyeth where she has spent the last two years managing the application of biomarkers in clinical trials. Previous to that, Mrs. Kaufman was Director Clinical Affairs at Viacell and Associate Director of Clinical Operations at Shire Biologics. Mrs. Klement has spent 4 years in clinical research at Pfizer and 10 years working on the management of multi-national clinical trials in the leading European clinical research organisations AMS and Innovex.
"As mtm enters this crucial clinical phase in the development of our assays we are delighted to appoint two such experienced individuals," said Ruediger Ridder, Chief Scientific Officer of mtm laboratories. "We have now put in place the right team to coordinate pivotal trials demonstrating the clinical utility of our in vitro diagnostic products based on the p16INK4a technology for the use in cervical cancer screening and diagnosis."
mtm laboratories AG is a privately held company based in Heidelberg, Germany with a wholly owned subsidiary in Westborough (MA), USA. The ISO 9001 and ISO 13485 certified company develops In Vitro Diagnostic test systems for the early detection and diagnosis of cancer with a focus on cervical cancer screening, the largest screening market in oncology. Based on mtm's proprietary p16INK4a biomarker, the Company is in the process of developing and clinically validating cell-based CINtec(R) assays as well as non cell-based IVD products.